Marcia Angell, former editor-in-chief of the New England Journal of Medicine, has argued that drug regulators were serving the interests of the drug companies rather than the patients. She has criticized the close relationship between drug companies and regulators, which she believes leads to conflicts of interest and compromises the safety and efficacy of drugs.